Skip to contentI
Inhibitor Therapeutics, Inc.
I
INTIInhibitor Therapeutics, Inc. Q3 2019 · 10-Q
Revenue$0.00$0.00no prior Q3 2018 on file Net Income-$678.55K-$678.55KN/M vs Q3 2018 EPS Diluted$0.00$0.00— vs Q3 2018 Operating Income-$682,921N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inhibitor Therapeutics, Inc. · CIK 1042418 · Engraved from SEC EDGAR
derived
ended Sep 30, 2019 · filed Nov 7, 2019 · 38 d after period end